DEVELOPMENT PIPELINE

We are leveraging our proprietary SNIPRx platform to discover, validate and build a robust clinical and pre-clinical pipeline of SL-based oncology therapeutics.

Development Pipeline

Program
Tumor Lesion
  • Discovery
  • IND-Enabling
  • Ph 1/2
  • Pivotal
Rights

Camonsertib
ATR Inhibitor

ATM + 16 additional lesions
  • Ph 1/2
TRESR: Monotherapy
  • Ph 1/2
TRESR: PARP (talazoparib) Combo
  • Ph 1/2
ATTACC: PARP (olaparib/niraparib) Combo
  • Ph 1/2
TRESR: Gemcitabine Combo
repare logo small

RP-6306
PKMYT1 Inhibitor

CCNE1,
FBXW7 + others
  • Ph 1/2
MYTHIC: Monotherapy
  • Ph 1/2
MAGNETIC: Gemcitabine Combo
  • Ph 1/2
MINOTAUR: FOLFIRI Combo
repare logo small

RP-2119
PolΘ Inhibitor

BRCA1/2 + others
  • IND.
repare logo small
ono logo

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small
Targets
ATR Inhibitor
Tumor Lesion
ATM + 16 additional lesions
Clinical Trial
TRESR: Monotherapy
Progress
Phase 1/2
Clinical Trial
TRESR: PARP (talazoparib) Combo
Progress
Phase 1/2
Clinical Trial
ATTACC: PARP (olaparib/niraparib) Combo
Progress
Phase 1/2
Clinical Trial
TRESR: Gemcitabine Combo
Progress
Phase 1/2
Rights
Repare
Roche
Targets
PKMYT1 Inhibitor
Tumor Lesion
CCNE1,
FBXW7 + others
Clinical Trial
MYTHIC: Monotherapy
Progress
Phase 1/2
Clinical Trial
MAGNETIC: Gemcitabine Combo
Progress
Phase 1/2
Clinical Trial
MINOTAUR: FOLFIRI Combo
Progress
Phase 1/2
Rights
Repare
Targets
PolΘ Inhibitor
Tumor Lesion
BRCA1/2 + others
Progress
IND. Enabling
Rights
Repare
Ono
Targets
Multiple Targets
Tumor Lesion
Undisclosed
Progress
Discovery
Rights
Repare
Targets
Multiple Targets
Tumor Lesion
Undisclosed
Progress
Discovery
Rights
Bristol Myers Squibb

Learn about our collection of ongoing clinical trials.